Work

Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients

Year: 2017

Type: review

Source: Journal of the American College of Cardiology

DOI: 10.1016/j.jacc.2017.03.563

Authors: Ankeet S. Bhatt, Adam D. DeVore, Tracy A. DeWald, Karl Swedberg, Robert J. Mentz

Institutions: Duke Medical Center, Duke University, Duke Clinical Research Institute, Imperial College London, University of Gothenburg

Language: English

Topic: Heart Failure Treatment and Management

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: American Heart Association, Amgen, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Gilead Sciences, Thoratec Corporation, HeartWare, Luitpold Pharmaceuticals, ResMed, Servier, National Institutes of Health

OpenAlex ID: W2615438558

FWCI: 0.652

Cites: 58

Cited by: 57

Related to: 10